B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Transcription of E2F targets under negative control by DREAM complex

REACTOME PATHWAY
Reactome: R-HSA-13622775 genes30 compounds

The Transcription of E2F targets under negative control by DREAM complex pathway (Reactome ID: R-HSA-1362277) involves 5 genes and is affected by 30 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

CDC25AHDAC1MYCPCNATOP2A

Compounds Affecting Transcription of E2F targets under negative control by DREAM complex

#CompoundTargets HitStudies
1Daunorubicin298
2myricetin-3-O-galactopyranoside [Supplementary Concept]300
3Genistein300
4Quercetin300
5Ethidium300
6Teniposide299
7Topotecan300
8Ciprofloxacin1,000
9fisetin78
10Aclarubicin300
11Dexrazoxane298
12Digitoxin300
13Epirubicin300
14Idarubicin299
15Vorinostat299
16trichostatic acid [Supplementary Concept] related to trichostatin300
17scriptaid53
18Valproic Acid296
19pictilisib25
20Butyric Acid300
21Ursolic Acid300
22Celecoxib295
23Bortezomib300
24Camptothecin300
25plumbagin [Supplementary Concept]300
26Vitamin K 3300
27Danazol298
28Methysergide300
29Oleanolic Acid300
30Triiodothyronine300

About the Transcription of E2F targets under negative control by DREAM complex Pathway

The Transcription of E2F targets under negative control by DREAM complex pathway is catalogued in Reactome (ID: R-HSA-1362277) and involves 5 genes. In the BiohacksAI corpus, 30 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include CDC25A, HDAC1, MYC, PCNA, TOP2A.